Stryker Corporation $SYK Shares Bought by Norinchukin Bank The

Norinchukin Bank The grew its position in shares of Stryker Corporation (NYSE:SYK) by 15.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,564 shares of the medical technology company’s stock after purchasing an additional 2,304 shares during the period. Norinchukin Bank The’s holdings in Stryker were worth $6,538,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of SYK. GAMMA Investing LLC lifted its holdings in shares of Stryker by 43,226.8% during the 1st quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company’s stock worth $772,390,000 after acquiring an additional 2,070,133 shares during the period. Nuveen LLC purchased a new position in Stryker in the first quarter valued at approximately $558,075,000. Price T Rowe Associates Inc. MD raised its holdings in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after buying an additional 1,021,496 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Stryker in the fourth quarter valued at approximately $154,140,000. Finally, Northern Trust Corp raised its holdings in Stryker by 13.2% in the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company’s stock valued at $1,298,426,000 after buying an additional 420,153 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 5.90% of the stock is currently owned by corporate insiders.

Stryker Trading Down 1.8%

SYK opened at $384.6550 on Friday. The firm has a market capitalization of $147.06 billion, a P/E ratio of 50.95, a P/E/G ratio of 2.85 and a beta of 0.91. The firm’s 50 day moving average is $387.17 and its 200-day moving average is $379.49. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. During the same quarter last year, the firm posted $2.81 earnings per share. The business’s quarterly revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s payout ratio is currently 44.50%.

Analyst Ratings Changes

Several research analysts recently commented on the stock. JMP Securities restated a “market perform” rating on shares of Stryker in a report on Monday, May 5th. BTIG Research restated a “buy” rating on shares of Stryker in a report on Monday, July 14th. Needham & Company LLC raised their price target on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Roth Mkm raised their price target on shares of Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Finally, Truist Financial set a $415.00 price target on shares of Stryker and gave the company a “hold” rating in a report on Monday, August 4th. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $430.10.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.